Center for Digestive and Liver Diseases, Inc.  © 2013  |  Privacy policy

like us

Protocol METO-IN-004

 

Phase 3 Study of Intranasal Metoclopramide in Men with Symptomatic Diabetic Gastroparesis

 

 

 

Diabetic men with clinical symptoms attributed to diabetic gastroparesis and documentation of delayed gastric emptying who meet the protocol-specified entry criteria will be randomized to Metoclopramide Nasal Spray 10 mg or placebo administered as a single intranasal spray four (4) times daily; 30 minutes before meals and at bedtime for a total of four (4) weeks.

 

 

 

I am interested in more information about this study.

SEND CLEAR